News
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Queensland’s Chief Health Officer has praised the new immunisation program that has protected hundreds of Queensland babies from Respiratory Syncytial Virus (RSV), as flu and Covid-19 cases spike ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback